CClinicalTrials.gg
RecruitingNCT07343011Updated Jan 15, 2026

Conjunctival Transpositional Surgery for Primary Pterygium

An interventional study of Conjunctival Transpositional Pterygium Surgery in Pterygium of the Conjunctiva and Cornea, sponsored by Zahedan University of Medical Sciences. Recruiting at 1 site in Iran. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Zahedan University of Medical Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This prospective single-arm interventional study evaluates the recurrence rate and functional outcomes following conjunctival transpositional pterygium surgery without bare sclera formation. The technique involves mobilization and transposition of the pterygium tissue while preserving Tenon's layer and avoiding adjunctive therapies.

02

Conditions studied

  • Pterygium of the Conjunctiva and Cornea

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 years or older
  • Primary pterygium involving the cornea
  • Ability to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Recurrent pterygium
  • Previous ocular surface surgery
  • Active ocular infection or inflammation
  • Severe ocular surface disease
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Pterygium patients

    Procedure: Conjunctival Transpositional Pterygium Surgery

Interventions

  • ProcedureConjunctival Transpositional Pterygium Surgery

    A conjunctival incision was created at the upper and lower limbus to allow adequate tissue mobilization. The pterygium tissue is dissected off the corneal surface without complete excision or creation of a bare sclera defect. The fibrovascular tissue is mobilized and transposed inferiorly within the subconjunctival plane and secured with absorbable sutures. Tenon's tissue is preserved, and no adjunctive therapy is used.

05

What researchers measure

Primary outcomes

  1. Pterygium Recurrence

    Recurrence is defined as fibrovascular regrowth toward the cornea or surgical failure.

    Time frame: 12 months

Secondary outcomes

  1. Visual Acuity

    Change in visual acuity measured in logMAR units.

    Time frame: 12 months

  2. Refractive Astigmatism

    Change in refractive astigmatism measured as cylindrical power in diopters.

    Time frame: 12 months

06

Study locations

1 of 1 sites recruiting
  • Alzahra Eye Hospital, Zahedan University of Medical Sciences
    Zahedan, Sistan and Balochistan, Iran
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07343011
Lead sponsor
Zahedan University of Medical Sciences
Responsible party
Mohammed Arish (Associate professor of ophthalmology, Zahedan University of Medical Sciences) — Principal investigator
First posted
Jan 15, 2026
Start date
May 21, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Mohammed Arish, MD, FRCS
Contact
mohammad.erish@zaums.ac.ir
09151419155

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion